These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28767678)

  • 21. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
    Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
    Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.
    Conn PM; Smithson DC; Hodder PS; Stewart MD; Behringer RR; Smith E; Ulloa-Aguirre A; Janovick JA
    Pharmacol Res; 2014 May; 83():38-51. PubMed ID: 24373832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coupling to Gs and G(q/11) of histamine H2 receptors heterologously expressed in adult rat atrial myocytes.
    Wellner-Kienitz MC; Bender K; Meyer T; Pott L
    Biochim Biophys Acta; 2003 Sep; 1642(1-2):67-77. PubMed ID: 12972295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
    Mouillac B; Mendre C
    Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.
    Rihakova L; Quiniou C; Hamdan FF; Kaul R; Brault S; Hou X; Lahaie I; Sapieha P; Hamel D; Shao Z; Gobeil F; Hardy P; Joyal JS; Nedev H; Duhamel F; Beauregard K; Heveker N; Saragovi HU; Guillon G; Bouvier M; Lubell WD; Chemtob S
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1009-18. PubMed ID: 19641130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calmodulin interacts with the V2 vasopressin receptor: elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium.
    Nickols HH; Shah VN; Chazin WJ; Limbird LE
    J Biol Chem; 2004 Nov; 279(45):46969-80. PubMed ID: 15319442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.
    de la Nuez Veulens A; Ginarte YMÁ; Fernandez RER; Leclerc F; Cabrera LAM
    J Mol Model; 2022 Jan; 28(2):31. PubMed ID: 34997307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
    Robben JH; Sze M; Knoers NV; Deen PM
    Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist.
    Serradeil-Le Gal C
    Cardiovasc Drug Rev; 2001; 19(3):201-14. PubMed ID: 11607038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
    Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.
    Janovick JA; Brothers SP; Cornea A; Bush E; Goulet MT; Ashton WT; Sauer DR; Haviv F; Greer J; Conn PM
    Mol Cell Endocrinol; 2007 Jun; 272(1-2):77-85. PubMed ID: 17555869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vasopressin receptors: structure/function relationships and signal transduction in target cells].
    Robert J; Clauser ER
    J Soc Biol; 2005; 199(4):351-9. PubMed ID: 16738530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes.
    Sadeghi H; Robertson GL; Bichet DG; Innamorati G; Birnbaumer M
    Mol Endocrinol; 1997 Nov; 11(12):1806-13. PubMed ID: 9369448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones.
    Szalai L; Sziráki A; Erdélyi LS; Kovács KB; Tóth M; Tóth AD; Turu G; Bonnet D; Mouillac B; Hunyady L; Balla A
    Front Pharmacol; 2022; 13():811836. PubMed ID: 35153784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Vasopressin Receptor 2 Mutant R137L Linked to the Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) Signals through an Alternative Pathway that Increases AQP2 Membrane Targeting Independently of S256 Phosphorylation.
    Ranieri M; Venneri M; Pellegrino T; Centrone M; Di Mise A; Cotecchia S; Tamma G; Valenti G
    Cells; 2020 May; 9(6):. PubMed ID: 32486031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
    Rochdi MD; Vargas GA; Carpentier E; Oligny-Longpré G; Chen S; Kovoor A; Gitelman SE; Rosenthal SM; von Zastrow M; Bouvier M
    Mol Pharmacol; 2010 May; 77(5):836-45. PubMed ID: 20159941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors.
    Schwieger I; Lautz K; Krause E; Rosenthal W; Wiesner B; Hermosilla R
    Mol Pharmacol; 2008 Mar; 73(3):697-708. PubMed ID: 18048502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo.
    Conn PM; Ulloa-Aguirre A; Ito J; Janovick JA
    Pharmacol Rev; 2007 Sep; 59(3):225-50. PubMed ID: 17878512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ligand recognition properties of the vasopressin V2 receptor studied under QSAR and molecular modeling strategies.
    Martínez-Archundia M; Colín-Astudillo B; Moreno-Vargas LM; Ramírez-Galicia G; Garduño-Juárez R; Deeb O; Contreras-Romo MC; Quintanar-Stephano A; Abarca-Rojano E; Correa-Basurto J
    Chem Biol Drug Des; 2017 Nov; 90(5):840-853. PubMed ID: 28419717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.